SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Making individualized drugs a reality
3 references·1 citing·16 second hop
Making individualized drugs a reality (2017)Making individualized drugs a realityOverspending driven by oversized single dose vials of cancer drugs (2016)Overspending driven by oversi…Towards a sustainable system of drug development (2014)Towards a sustainable system …Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group (2012)Challenges in the Development…We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis. (2021)We Cannot Win the Access to M…Can the pharmaceutical industry reduce attrition rates? (2004)Lessons from 60 years of pharmaceutical innovation (2009)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)How expected outcomes, stakeholders, and institutions influence corporate social responsibility at different levels of large basic needs firms (2018)Cost-Effectiveness in Health and Medicine (1996)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)Methods for the Economic Evaluation of Health Care Programmes (2005)The Future of Precision Medicine: Potential Impacts for Health Technology Assessment (2018)Cost-effectiveness of precision medicine: a scoping review (2019)Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group (2020)Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand (2007)Medicine Shortages: Gaps Between Countries and Global Perspectives (2019)Decolonising global health: if not now, when? (2020)A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer (2017)Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value (2020)Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis (2024)
this work references cited by second hop

References

  • 2012Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group161 cited
  • 2016Overspending driven by oversized single dose vials of cancer drugs155 cited
  • 2014Towards a sustainable system of drug development58 cited

Cited by

  • 2021We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis.47 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work